ClinicalTrials.gg
CompletedNCT02564952Updated Sep 28, 2022Results posted

An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

A Phase 2 interventional study of GWP42003-P and Clobazam in Epilepsy, sponsored by Jazz Pharmaceuticals. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing cannabidiol in Epilepsy — 2 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Epilepsy.

Enrollment
18th of 20
18 · median 35
Started
2016
with 3 others
Phase 2
6 of 20
none open now
Registered
8th of 20
by date
Lead sponsor
11 of 20
Jazz Pharmaceuticals

Among the 20 studies testing cannabidiol in Epilepsy, this one is the 18th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 2, and was the 8th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 20 studies testing cannabidiol in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing cannabidiol in Epilepsy, or all of them as a file.
02

Study summary

This study consisted of 2 parts: a double-blind (DB) phase and an open-label extension (OLE) phase. Only the OLE phase is described in this record. The OLE phase was a safety study. All participants received GWP42003-P initially titrated to 20 milligrams (mg)/kilograms (kg)/day; however, investigators subsequently decreased or increased the participant's dose to a maximum of 30 mg/kg/day (no minimum).

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Cannabidiol (CBD)
  • GWP42003-P
  • Clobazam
  • Epidiolex
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must have had epilepsy, as determined by the investigator, and must have been taking CLB.
  • Participant must have had a documented magnetic resonance imaging/computerized tomography of the brain ruling out a progressive neurologic condition.
  • Participant must have experienced at least 1 seizure of any type (that is, convulsive: tonic-clonic, tonic, clonic, atonic; focal: focal seizures with retained consciousness and a motor component, focal seizures with impaired consciousness, focal seizures evolving to bilateral secondary generalization) within the 2 months prior to randomization.
  • Participant must have been taking CLB and no more than 2 other antiepileptic drugs (AEDs) during the course of the study. However, any participants who were taking these medications after screening were not withdrawn from the study unless there were safety concerns.
  • AED(s), including CLB, must have been stable for 4 weeks prior to screening and regimen must have remained stable throughout the duration of the double-blind phase of the study.
  • Intervention with vagus nerve stimulation and/or ketogenic diet must have been stable for 4 weeks prior to Baseline and participant/caregiver must have been willing to maintain a stable regimen throughout the double-blind phase of the study.

Key Exclusion Criteria:

  • Participant had unstable medical conditions other than epilepsy.
  • Participants were on CLB at doses above 20 mg per day.
  • Participants taking CLB intermittently as rescue medication.
  • Participant had a history of symptoms related to a drop in blood pressure due to postural changes (for example, dizziness, light-headedness, blurred vision, palpitations, weakness, syncope).
  • Participant had any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale in the last month or at screening.
  • Participant had clinically relevant symptoms or a clinically significant illness, other than epilepsy in the 4 weeks prior to screening or enrollment, other than epilepsy.
  • Participant had consumed alcohol during the 7 days prior to enrollment and was unwilling to abstain during the double-blind phase of the study.
  • Participant was currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to study entry.
  • Participant had any known or suspected history of any drug abuse or addiction.
  • Participant was unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex) for the duration for the study.
  • Participant consumed grapefruit or grapefruit juice 7 days prior to enrollment and was unwilling to abstain from drinking grapefruit juice within 7 days of pharmacokinetic visits.
  • Participant had any known or suspected to cannabinoids or any of the of the IMP, for example, sesame oil.
  • Participant received an IMP within the 12 weeks prior to the screening visit.
  • Participant had significantly impaired hepatic function at the screening or randomization visit, defined as any of the following: (A) (ALT) or aspartate aminotransferase (AST) > 5 × (ULN). (B) ALT or AST > 3 × ULN and total > 2 × ULN or > 1.5. (C) ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    GWP42003-P

    Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P. Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant.

    Drug: GWP42003-P · Drug: Clobazam

Interventions

  • GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.

    Also known as: Cannabidiol (CBD), Epidiolex

  • Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.

    Also known as: CLB

06

What researchers measure

Primary outcomes

  1. Number Of Participants Who Experienced Severe OLE-Emergent AEs

    An OLE-emergent AE was defined as an AE with an onset date after the first dose of IMP in the OLE phase of the study. The number of participants who experienced 1 or more severe OLE-emergent AEs after the first dose of IMP in the OLE phase of the study up to the Safety follow-up visit (28 \[± 3\] days following the last dose of IMP) is presented. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Postdose on Day 2 of Visit 4 up to Safety follow-up (28 [± 3] days following the last dose of IMP)

07

Results

Posted Sep 11, 2018

Participant flow

All participants were enrolled by invitation into the open-label extension (OLE) phase after completing the double-blind phase of the study.

Participant flow — Overall Study
MilestoneGWP42003-P
Started18
Received at least 1 dose of study drug18
Completed ole titration period16
Completed7
Not completed11
Withdrew: Adverse event6
Withdrew: Lost to follow-up1
Withdrew: Participant withdrawn by investigator1
Withdrew: Withdrawal by subject1
Withdrew: Low efficacy1
Withdrew: Participant met withdrawal criteria1

Outcome measures

PrimaryNumber Of Participants Who Experienced Severe OLE-Emergent AEs

An OLE-emergent AE was defined as an AE with an onset date after the first dose of IMP in the OLE phase of the study. The number of participants who experienced 1 or more severe OLE-emergent AEs after the first dose of IMP in the OLE phase of the study up to the Safety follow-up visit (28 \[± 3\] days following the last dose of IMP) is presented. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Postdose on Day 2 of Visit 4 up to Safety follow-up (28 [± 3] days following the last dose of IMP)
Reported as:
Count of participants · Participants
Number Of Participants Who Experienced Severe OLE-Emergent AEs
ParticipantsGWP42003-P
Number Of Participants Who Experienced Severe OLE-Emergent AEs4

Adverse events

Collected over Postdose on Day 2 of Visit 4 up to Safety follow-up (28 [± 3] days following the last dose of IMP). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P0/18 (0%)2/18 (11.1%)17/18 (94.4%)
Most frequent serious events
Most frequent serious events
EventGWP42003-P
Alanine aminotransferase abnormalInvestigations1/18
Aspartate aminotransferase abnormalInvestigations1/18
Gamma-glutamyltransferase abnormalInvestigations1/18
SeizureNervous system disorders1/18
Status epilepticusNervous system disorders1/18
Most frequent other events
Showing 10 of 42
Most frequent other events
EventGWP42003-P
DiarrhoeaGastrointestinal disorders8/18
SomnolenceNervous system disorders7/18
DizzinessNervous system disorders4/18
HeadacheNervous system disorders4/18
VomitingGastrointestinal disorders3/18
FatigueGeneral disorders2/18
Respiratory tract infectionInfections and infestations2/18
HyponatraemiaMetabolism and nutrition disorders2/18
SeizureNervous system disorders2/18
IrritabilityPsychiatric disorders2/18

Baseline characteristics

The study population included all participants who completed the GWEP1428 double-blind phase and entered the OLE phase of the study.

Age, Continuous
Age, Continuous(years)GWP42003-P
Mean36.35 ± 9.05
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P
Female8
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GWP42003-P
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Any History Of Current Seizures
Any History Of Current Seizures(Participants)GWP42003-P
Count of participants18
08

Study locations

6 sites
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Birmingham, B15 2FG, United Kingdom
  • Brighton, BN2 5BE, United Kingdom
  • Leeds, LS1 3EX, United Kingdom
  • Salford, M6 8HD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jun 2017, 14 months.

Results were first posted in Sep 2018, 1 year 3 months after primary completion.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2015
First posted
Oct 1, 2015
StartActual
Mar 11, 2016
Primary completionActual
Jun 7, 2017
CompletionActual
Jun 7, 2017
Results first posted
Sep 11, 2018
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02564952
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Mar 11, 2016
Primary completion
Jun 7, 2017
Completion
Jun 7, 2017
Results posted
Sep 11, 2018
Last update
Sep 28, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cannabidiol · Clobazam

Start the discussion